 |
||||
| International Lyme And Associated Diseases Society | ||||
|
Insurance companies have use evidence from trials to deny treatment. This published epidemologoic perspective details the limitations of the evidence used to deny antibiotic therapy. The abstract and part of the discussion are attached.
ILADS continues to push for open dialogue betwen professional. Lisa Phillips of Neurology Times helped contribute to the dialogue. The following sare quotations from the article that highlight the opportunities for dialogue.
Guidelines of the Infectious Disease Society of America (IDSA) fall short of meeting the needs for diagnosis and treatment of individuals with chronic Lyme disease. The latest IDSA Guidelines (2000) fail to take into account the compelling, peer-reviewed, published evidence confirming persistent, recurrent and refractory Lyme disease and, in fact, deny its existence. ILADS identified the need for new and expanded guidelines for the diagnosis and treatment of Lyme and associated diseases. In 2001, a working party was formed to evaluate current practices and to encourage new standards of care.
ILADS members voice concern regarding newly selected IDSA review panel. Experienced physicians excluded from participation in the new IDSA guideline committee who billed for more the $10,000 per year seeing Lyme diseasae patients were excluded from participation.
The ILADS treatment guidelines becomes a standard of care. It specifies appropriate treatment based on scientific evidence and collaboration between medical professionals involved in the treatment of Lyme disease.
A professional society was needed to help understand Lyme disease and support professionals to advance the standard of care.
Email Us
Twitter
Facebook